Table 2.
Characteristics of matched pairs
| Myosteatosis n = 98 | No Myosteatosis n = 98 | LMM n = 102 | Normal MM n = 102 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | p | N | % | N | % | p | |
| Age | 0.88 | 1 | ||||||||
| < 61 | 62 | 63.3 | 64 | 65.3 | 68 | 66.7 | 69 | 67.6 | ||
| > = 61 | 36 | 36.7 | 34 | 34.7 | 34 | 33.3 | 33 | 32.4 | ||
| Sex | 0.60 | 0.85 | ||||||||
| Female | 22 | 22.4 | 18 | 18.4 | 18 | 17.6 | 16 | 15.7 | ||
| Male | 76 | 77.6 | 80 | 81.6 | 84 | 82.4 | 86 | 84.3 | ||
| Race | 0.65 | 0.81 | ||||||||
| White | 86 | 87.8 | 89 | 90.8 | 94 | 92.2 | 92 | 90.2 | ||
| BIPOC | 12 | 12.2 | 9 | 9.2 | 8 | 7.8 | 10 | 9.8 | ||
| Comorbidities | 0.96 | 0.86 | ||||||||
| None | 16 | 16.3 | 18 | 18.4 | 17 | 16.7 | 19 | 18.6 | ||
| 1 | 25 | 25.5 | 27 | 27.6 | 25 | 24.5 | 27 | 26.5 | ||
| 2 | 16 | 16.3 | 14 | 14.3 | 14 | 13.7 | 16 | 15.7 | ||
| 3 + | 41 | 41.8 | 39 | 39.8 | 46 | 45.1 | 40 | 39.2 | ||
| Tumor site | 0.79 | 0.66 | ||||||||
| Oropharynx | 44 | 44.9 | 46 | 46.9 | 48 | 47.1 | 53 | 52.0 | ||
| Larynx | 31 | 31.6 | 33 | 33.7 | 32 | 31.4 | 26 | 25.5 | ||
| Other | 23 | 23.5 | 19 | 19.4 | 22 | 21.6 | 23 | 22.5 | ||
| AJCC stage | 0.34 | 0.98 | ||||||||
| 0-II | 28 | 28.6 | 32 | 32.7 | 30 | 29.4 | 32 | 31.4 | ||
| III | 19 | 19.4 | 25 | 25.5 | 24 | 23.5 | 24 | 23.5 | ||
| IV | 51 | 52.0 | 41 | 41.8 | 48 | 47.1 | 46 | 45.1 | ||
| HPV | 0.81 | 0.68 | ||||||||
| Positive | 21 | 21.4 | 23 | 23.5 | 22 | 21.6 | 26 | 25.5 | ||
| Negative | 29 | 29.6 | 32 | 32.7 | 35 | 34.3 | 37 | 36.3 | ||
| N/A | 48 | 49.0 | 43 | 43.9 | 45 | 44.1 | 39 | 38.2 | ||
| Treatment | 1 | 1 | ||||||||
| RT only | 7 | 7.1 | 8 | 8.2 | 6 | 5.9 | 6 | 5.9 | ||
| Chemoradiation | 91 | 92.9 | 90 | 91.8 | 96 | 94.1 | 96 | 94.1 | ||
| Smoking | 0.98 | 0.80 | ||||||||
| Current | 20 | 20.4 | 20 | 20.4 | 22 | 21.6 | 26 | 25.5 | ||
| Former | 45 | 45.9 | 47 | 48.0 | 50 | 49.0 | 48 | 47.1 | ||
| Never | 33 | 33.7 | 31 | 31.6 | 30 | 29.4 | 28 | 27.5 | ||
| Alcohol | 0.92 | 0.75 | ||||||||
| Current | 18 | 18.4 | 18 | 18.4 | 19 | 18.6 | 16 | 15.7 | ||
| Former | 20 | 20.4 | 21 | 21.4 | 20 | 19.6 | 26 | 25.5 | ||
| Never | 56 | 57.1 | 57 | 58.2 | 60 | 58.8 | 58 | 56.9 | ||
| N/A | 4 | 4.1 | 2 | 2.0 | 3 | 2.9 | 2 | 2.0 | ||
| Muscle mass | 1 | NA | ||||||||
| Normal | 49 | 50.0 | 48 | 49.0 | 0 | 0.0 | 102 | 100.0 | ||
| Low | 49 | 50.0 | 50 | 51.0 | 102 | 100.0 | 0 | 0.0 | ||
| Myosteatosis | NA | 1 | ||||||||
| No | 0 | 0.0 | 98 | 100.0 | 53 | 52.0 | 53 | 52.0 | ||
| Yes | 98 | 100.0 | 0 | 0.0 | 49 | 48.0 | 49 | 48.0 | ||
Abbreviations: AJCC American Joint Committee on Cancer, BIPOC Black Indigenous People of Color, LMM Low muscle mass, MM Muscle mass, RT Radiation therapy
Data are presented as frequency (percent), mean (SD)